Analyst Price Targets — MYGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:58 pm | Lu Li | UBS | $6.00 | $4.71 | TheFly | Myriad Genetics price target lowered to $6 from $8 at UBS |
| November 4, 2025 12:36 pm | Lu Li | UBS | $8.00 | $8.18 | TheFly | Myriad Genetics price target raised to $8 from $6 at UBS |
| May 7, 2025 1:14 pm | Bill Bonello | Craig-Hallum | $18.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum |
| May 7, 2025 12:18 pm | Lu Li | UBS | $7.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $7 from $16 at UBS |
| May 7, 2025 10:45 am | Brandon Couillard | Wells Fargo | $6.00 | $7.27 | TheFly | Myriad Genetics downgraded to Equal Weight from Overweight at Wells Fargo |
| March 12, 2025 9:17 am | — | Piper Sandler | $12.50 | $10.41 | TheFly | Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler |
| March 4, 2025 11:31 am | — | Piper Sandler | $11.50 | $10.42 | TheFly | Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler |
| December 9, 2024 11:07 am | Puneet Souda | Leerink Partners | $21.00 | $15.15 | StreetInsider | Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform |
| October 14, 2024 10:25 am | Sung Ji Nam | Scotiabank | $34.00 | $24.67 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN) |
| September 19, 2024 5:04 am | Tejas Savant | Morgan Stanley | $32.00 | $28.47 | TheFly | Myriad Genetics initiated with an Equal Weight at Morgan Stanley |
Latest News for MYGN
Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cancer—showed resilience, offsetting reimbursement headwinds in mental health and weakness in prenatal testing. Cost-cutting drove sharply lower operating expenses and narrowed losses, while gross margins remained stable at…
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MYGN.
U.S. House Trading
No House trades found for MYGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.